Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management
- 5 December 2022
- journal article
- research article
- Published by Elsevier BV in Pregnancy Hypertension
- Vol. 31, 32-37
- https://doi.org/10.1016/j.preghy.2022.11.008
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary ReviewMayo Clinic Proceedings, 2020
- Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunctionAmerican Journal of Hematology, 2020
- SARS‐CoV2 and pregnancy: An invisible enemy?American Journal of Reproductive Immunology, 2020
- Pre‐eclampsia‐like syndrome induced by severe COVID‐19: a prospective observational studyBJOG: An International Journal of Obstetrics and Gynaecology, 2020
- Pre-eclampsia/EclampsiaRBGO Gynecology & Obstetrics, 2019
- Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected PreeclampsiaThe New England Journal of Medicine, 2016
- Global causes of maternal death: a WHO systematic analysisThe Lancet. Global Health, 2014
- The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHPPregnancy Hypertension, 2014
- Global and regional estimates of preeclampsia and eclampsia: a systematic reviewEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2013
- Preeclampsia, a Disease of the Maternal EndotheliumCirculation, 2011